The Podler technology is currently under development within Q-linea and could enable a significant improvement in blood culturing for patients with blood infections, of which sepsis is the most severe condition. Podler is a handheld fully autonomous device to incubate and detect growth in blood culture bottles. The technology can make use of valuable transportation time, time which may be wasted when using traditional methods. The use of transportation time could enable much faster time to result for patients with blood infections and provide equal care to patients with severe infections. 

“This is an important step in our strategy for the commercialization of the Podler technology. The traditional blood culturing market is dominated by only a few major companies, and to have early interest in evaluating Podler is of course a very positive first step. It proves the serious interest we are seeing for our technology which is very positive for our future development and long term go to market strategy for Podler,” said Jonas Jarvius, CEO of Q-linea.